טוען...
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
The PI3K/Akt/mTOR (phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin) pathway regulates several key cellular functions and its dysregulation creates an environment that promotes tumorigenesis as well as resistance to therapy. The mTOR inhibitor everolimus has emerged as a...
שמור ב:
Main Authors: | , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Dove Medical Press
2013
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3929343/ https://ncbi.nlm.nih.gov/pubmed/24648755 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S30131 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|